Falk Gastro Info 5/2017

Video

Video course abdominal ultrasound

Examination of the liver: Perihepatic lymph nodes

Author: Prof. Dr. Christoph F. Dietrich, Caritas Krankenhaus Bad Mergentheim.

Please switch on your loudspeakers!

Link to Falk Mediacenter

Latest research in brief:

Bowel

Text:

Jiang ZD et al, Aliment Pharmacol Ther. 2017;45(7):899–908

Impact of the preparation of microbiota during fecal transplantation: Fresh microbiota are equally effective as frozen and slightly more effective than lyophilized stool samples to treat recurrent Clostridium difficile infection.

Link to text

Text:

Lightner AL et al, J Crohns Colitis. 2017;11(2):185–90

Postoperative outcomes in Vedolizumab-treated patients with inflammatory bowel disease: Vedolizumab therapy within 12 weeks of surgery predicts risk of 30-day postoperative surgical site infection in a retrospective cohort study.

Link to text

Text:

Christie J et al, Am J Gastroenterol. 2017;112(2):356–64

Effectiveness of Lubiprostone on constipation symptoms in diabetic patients: Lubiprostone is safe and effective in increasing spontaneous bowel movements and decreasing colon transit time, but does not influence quality of life and severity of gastrointestinal symptoms.

Link to text

Liver Biliary Tracts

Text:

Tsukuda S et al, Hepatology. 2017;65(4):1104–16

Hepatitis B: Chemical, biochemical and cell culture data indicate that proanthocyanidines may be potent, well-tolerated, and broadly active inhibitors against hepatitis B virus (HBV). They directly target the large HBV surface protein (L-HBsAg) and inhibit its interaction with the cell receptor NTCP (sodium taurocholate cotransporting polypeptide).

Link to text

Text:

Hegade VS et al, Lancet. 2017;389(10074):1114–23

Primary biliary cholangitis (PBC): GSK2330672, an inhibitor of the ileal bile acid transporter, substantially reduced pruritus in patients with PBC in a small phase 2a study. This drug may be a promising therapeutic addition to ursodeoxycholic acid in patients with PBC and pruritus. Diarrhea is a relevant and potentially limiting adverse effect.

Link to text

Text:

Vergis N et al, Gastroenterology. 2017;152(5):1068–77.e4

Severe alcoholic hepatitis: Prednisolone therapy increases the risk for developing serious infections and infections after treatment. Levels of circulating bacterial DNA before treatment may identify patients at high risk of infection if treated with prednisolone and may thus help to select optimal therapies for patients with severe alcoholic hepatitis.

Link to text

Oesophagus Stomach Duodenum

Text:

Guthikonda A et al, Am J Gastroenterol. 2017;112(1):87–94

Clinical outcomes following recurrence of intestinal metaplasia after treatment of Barrett’s esophagus with radiofrequency ablation: Although most patients with recurrent Barrett’s esophagus achieve remission, 1,8% of patients progress to invasive adenocarcinoma. Length of Barrett’s esophagus is a strong risk factor and most dysplastic recurrences are located in the cardia. Therefore, random biopsies of the cardia are advisable during surveillance endoscopy.

Link to text

Text:

Stanley AJ et al, BMJ. 2017;356:i6432

Comparison of scoring systems for upper gastrointestinal bleeding: The Glasgow Blatchford score has a high accuracy to predict the need for hospital-based interventions or death. Patients with scores ≤ 1 points can be safely managed as outpatients.

Link to text

Text:

Dellon ES et al, Gastroenterology. 2017;152(4):776–86.e5

Eosinophilic esophagitis: A novel oral suspension of budesonide improves symptomatic, endoscopic and histologic parameters compared with placebo.

Link to text

Pancreas

Text:

Raphael KL et al, Pancreas. 2017;46(2):237–43

Pancreatic insufficiency and tobacco exposure: This small study suggests that tobacco exposure is independently associated with exocrine insufficiency in patients without prior diagnosis of pancreatic disease.

Link to text

International Symposia and Workshops

Symposium 207

Gut Microbiome and Mucosal or Systemic Dysfunction: Mechanisms, Clinical Manifestations and Interventions

May 19 – 20, 2017, Brisbane, Australia
Brisbane Convention & Exhibition Centre, Merivale St & Glenelg Street, South Brisbane, QLD 4101, Australia

Program

Registration

Online registration

Current Falk literature:

NEW
Rectal Treatment of Inflammatory Bowel Diseases

Author: P. Frei, G. Rogler

(27 pages)